Please assess the completion status of the following clinical trial:

Trial Title: Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suitable candidate for surgery (meets appropriate performance status, no significant cardiac/renal/hepatic dysfunction~* Diagnosis of pelvic malignancy (suspected/confirmed ovarian, endometrial/uterine, cervical cancers, and vulvar cancers) undergoing surgical debulking,~* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to surgery,~* Women must not be breastfeeding, WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) apixaban plus 5 half-lives of study drug apixaban (2.5 days) plus 30 days (duration of ovulatory cycle) for a total of 32.5 days post-treatment completion.~Exclusion Criteria:~* Malignancy or mass that is non-gynecologic in origin (mass/tumor of origin other than reproductive organ such as rectal, abdominal, breast)~* Positive pregnancy test on day of surgery,~* Known history of Venous (Thromboembolism) VTE prior to diagnosis (DVT or Pulmonary Embolism (PE)) due to increased underlying risk of new event~* Concomitant NSAIDS or other anticoagulant/antiplatelet therapy including Acetylsalicylic Acid (Aspirin) (ASA) \>81mg/day,~* Selective serotonin re uptake inhibitor (SSRIs) and Serotonin-nor-epinephrine re uptake inhibitor (SNRIs) (common anti-depressant therapies),~* Uncontrolled severe hypertension (systolic \>200 mmHg or diastolic \>120 mmHg),~* With prosthetic heart valves,~* Active bleeding condition (not limited to: thrombocytopenia, haemophilias, potential bleeding lesions, recent trauma or surgery, recent stroke, confirmed intracranial or intraspinal bleeding),~* Known or documented bleeding disorders not limited to: anti-phospholipid syndrome, homozygotes for Factor V Leiden deficiency, antithrombin III deficiency, protein C deficiency, Protein S deficiency, hyperhomocysteinemia, systemic lupus erythematous, or Prothrombin G2020 gene mutation,~* Significant renal disease as defined by creatinine clearance less than 30 mL/min,~* Significant liver disease as defined as Aspartate Transaminase (AST) or Alanine Transaminase (ALT) twice than normal,~* Concomitant use of dual strong inhibitors or inducers (CYP3A4, P-gp)~* Protein C deficiency (increased risk of skin necrosis do those on injectable anticoagulation),~* Documented allergy to apixaban and/or enoxaparin,~* Patient's deemed otherwise clinically unfit for clinical trial per Investigator's discretion

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Oral apixaban (Type: EXPERIMENTAL): Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
- Subcutaneous enoxaparin (Type: ACTIVE_COMPARATOR): Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).